Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$3.49
-3.1%
$3.81
$2.76
$13.50
$195.86MN/A436,619 shs432,187 shs
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$3.85
-1.5%
$3.02
$2.38
$5.54
$234.14M-0.16329,459 shs685,318 shs
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
$2.40
-8.0%
$0.00
$2.28
$24.15
$48.81M0.4835,835 shs63,337 shs
ProKidney Corp. stock logo
PROK
ProKidney
$3.37
-8.7%
$1.16
$0.46
$7.13
$1.08B1.263.50 million shs34.41 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-3.06%+0.29%+11.15%-31.16%-69.09%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-1.53%+12.57%+34.15%+28.33%+47.51%
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
-8.05%-6.98%-9.09%+239,999,900.00%+239,999,900.00%
ProKidney Corp. stock logo
PROK
ProKidney
-8.67%-9.65%+302.00%+321.25%+41.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
3.4501 of 5 stars
3.60.00.00.02.93.31.3
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1.8256 of 5 stars
3.51.00.00.02.81.70.0
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
3.519 of 5 stars
3.24.00.00.03.04.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.22
Buy$22.86554.93% Upside
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3.00
Buy$9.00133.77% Upside
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
0.00
N/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
2.40
Hold$6.2585.46% Upside

Current Analyst Ratings Breakdown

Latest KLRS, PROK, ALMS, and ELDN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
ProKidney Corp. stock logo
PROK
ProKidney
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $8.00
7/14/2025
ProKidney Corp. stock logo
PROK
ProKidney
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $7.00
7/9/2025
ProKidney Corp. stock logo
PROK
ProKidney
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $9.00
6/30/2025
ProKidney Corp. stock logo
PROK
ProKidney
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00 ➝ $1.00
6/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
6/10/2025
Alumis Inc. stock logo
ALMS
Alumis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$18.00
5/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $25.00
4/30/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/22/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$5.51 per shareN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.98 per shareN/A
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/AN/AN/AN/A$22.47 per shareN/A
ProKidney Corp. stock logo
PROK
ProKidney
$80K12,329.99N/AN/A($3.41) per share-0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-406.27%-107.29%8/12/2025 (Estimated)
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
-$58.77MN/A0.00N/AN/A-62.08%-54.69%N/A
ProKidney Corp. stock logo
PROK
ProKidney
-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)

Latest KLRS, PROK, ALMS, and ELDN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.11N/AN/AN/A$1.80 millionN/A
8/8/2025Q2 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.47-$1.82-$0.35-$1.82N/AN/A
5/14/2025Q1 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.28-$0.08+$0.20-$0.08N/AN/A
5/12/2025Q1 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.13+$0.03-$0.13N/A$0.23 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
3.73
3.73
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
13.90
13.91
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
N/A
14.31
14.31
ProKidney Corp. stock logo
PROK
ProKidney
N/A
10.96
10.96

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
66.05%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
74.99%
ProKidney Corp. stock logo
PROK
ProKidney
41.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A54.41 million32.26 millionN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1059.88 million52.52 millionOptionable
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
11018.70 million4.68 millionN/A
ProKidney Corp. stock logo
PROK
ProKidney
3292.70 million171.26 millionOptionable

Recent News About These Companies

ProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst Upgrade
ProKidney (NASDAQ:PROK) Shares Gap Up on Analyst Upgrade
ProKidney's (PROK) "Buy" Rating Reiterated at Citigroup

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$3.49 -0.11 (-3.06%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$3.52 +0.03 (+1.00%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$3.85 -0.06 (-1.53%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$3.74 -0.11 (-2.73%)
As of 08:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Kalaris Therapeutics stock logo

Kalaris Therapeutics NASDAQ:KLRS

$2.40 -0.21 (-8.05%)
As of 07/15/2025 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

ProKidney stock logo

ProKidney NASDAQ:PROK

$3.37 -0.32 (-8.67%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$3.38 +0.00 (+0.15%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.